Comparison of Oxidative Effects of Two Different Administration Form of Oxybutynin in the Potential Target Tissues

Overview

Journal Adv Urol

Publisher Wiley

Specialty Urology

Date 2019 Jan 25

PMID 30675153

Authors

Kaan Kaltalioglu

Fatmanur Tugcu-Demiroz

Fusun Acarturk

Barbaros Balabanli

Sule Coskun-Cevher

Affiliations

Soon will be listed here.

Abstract

Oxybutynin is an important anticholinergic agent that prevents uncontrolled contractions in the treatment of overactive bladder (OAB). However, drugs containing oxybutynin have significant side effects such as dry eyes, dry mouth, increased heart rate, constipation, blurred vision, and confusion. In recent years, new delivery methods for this agent are being searched. One of them is vaginal delivery. In this study, we aimed to compare the effects of oxybutynin on oxidative parameters in the potential target tissues of the oral and vaginal delivery. Female New Zealand white rabbits (=12) were divided into two groups: oral delivery and vaginal delivery. The animals were sacrificed 48 h after administration and nitric oxide (NOx), thiobarbituric acid-reactive substances (TBARs), and glutathione (GSH) levels were determined spectrophotometrically in the aorta, salivary gland, and small intestine tissue samples. Vaginal delivery significantly decreased NOx levels in all tissue samples as compared to oral delivery ( < 0.05). Moreover, it reduced TBARs levels in salivary gland and aorta tissue samples ( < 0.05). In the light on these findings, it can be said that vaginal delivery may decrease the oxidant-induced side effects of oxybutynin as compared to oral delivery.

References

Yamauchi Y, Matsuno T, Omata K, Satoh T . Relationship between hyposalivation and oxidative stress in aging mice. J Clin Biochem Nutr. 2017; 61(1):40-46. PMC: 5525015. DOI: 10.3164/jcbn.16-79. View

Breseghelo M, Guillo L, Nogueira T, Leles C . Nitric Oxide Concentration and Other Salivary Changes after Insertion of New Complete Dentures in Edentulous Subjects. Int J Dent. 2016; 2016:8351427. PMC: 4789480. DOI: 10.1155/2016/8351427. View

Cohn J, Brown E, Reynolds W, Kaufman M, Milam D, Dmochowski R . An update on the use of transdermal oxybutynin in the management of overactive bladder disorder. Ther Adv Urol. 2016; 8(2):83-90. PMC: 4772360. DOI: 10.1177/1756287215626312. View

Ryo K, Takahashi A, Tamaki Y, Ohnishi-Kameyama M, Inoue H, Saito I . Therapeutic effects of isoflavones on impaired salivary secretion. J Clin Biochem Nutr. 2014; 55(3):168-73. PMC: 4227830. DOI: 10.3164/jcbn.14-49. View

Domingos P, Prado A, Wong A, Gehring C, Feijo J . Nitric oxide: a multitasked signaling gas in plants. Mol Plant. 2015; 8(4):506-20. DOI: 10.1016/j.molp.2014.12.010. View

Eapen R, Radomski S . Review of the epidemiology of overactive bladder. Res Rep Urol. 2016; 8:71-6. PMC: 4902138. DOI: 10.2147/RRU.S102441. View

Proctor G, Carpenter G . Salivary secretion: mechanism and neural regulation. Monogr Oral Sci. 2014; 24:14-29. DOI: 10.1159/000358781. View

Niki E . Lipid peroxidation products as oxidative stress biomarkers. Biofactors. 2009; 34(2):171-80. DOI: 10.1002/biof.5520340208. View

Phaniendra A, Jestadi D, Periyasamy L . Free radicals: properties, sources, targets, and their implication in various diseases. Indian J Clin Biochem. 2015; 30(1):11-26. PMC: 4310837. DOI: 10.1007/s12291-014-0446-0. View

10.

Vozmediano-Chicharro R, Madurga B, Blasco P . Efficacy of Transdermal Oxybutynin in the Treatment of Overactive Bladder Syndrome: Does It Make Sense Using It in 2017?. Adv Urol. 2018; 2018:6782736. PMC: 6087608. DOI: 10.1155/2018/6782736. View

11.

Konttinen Y, Platts L, Tuominen S, Eklund K, Santavirta N, Tornwall J . Role of nitric oxide in Sjögren's syndrome. Arthritis Rheum. 1997; 40(5):875-83. DOI: 10.1002/art.1780400515. View

12.

Tugcu-Demiroz F, Acarturk F, Erdogan D . Development of long-acting bioadhesive vaginal gels of oxybutynin: formulation, in vitro and in vivo evaluations. Int J Pharm. 2013; 457(1):25-39. DOI: 10.1016/j.ijpharm.2013.09.003. View

13.

Coyne K, Sexton C, Vats V, Thompson C, Kopp Z, Milsom I . National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011; 77(5):1081-7. DOI: 10.1016/j.urology.2010.08.039. View

14.

Potter T, Neun B, Stern S . Assay to detect lipid peroxidation upon exposure to nanoparticles. Methods Mol Biol. 2010; 697:181-9. DOI: 10.1007/978-1-60327-198-1_19. View

15.

Yamada T, Ryo K, Tai Y, Tamaki Y, Inoue H, Mishima K . Evaluation of therapeutic effects of astaxanthin on impairments in salivary secretion. J Clin Biochem Nutr. 2010; 47(2):130-7. PMC: 2935153. DOI: 10.3164/jcbn.10-31. View

16.

Nojiri H, Shimizu T, Funakoshi M, Yamaguchi O, Zhou H, Kawakami S . Oxidative stress causes heart failure with impaired mitochondrial respiration. J Biol Chem. 2006; 281(44):33789-801. DOI: 10.1074/jbc.M602118200. View

17.

Jayarajan J, Radomski S . Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life. Res Rep Urol. 2014; 6:1-16. PMC: 3862648. DOI: 10.2147/RRU.S40034. View

18.

Pande M, Flora S . Lead induced oxidative damage and its response to combined administration of alpha-lipoic acid and succimers in rats. Toxicology. 2002; 177(2-3):187-96. DOI: 10.1016/s0300-483x(02)00223-8. View

19.

Abrams P, Andersson K . Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007; 100(5):987-1006. DOI: 10.1111/j.1464-410X.2007.07205.x. View

20.

Gamboa A, Okamoto L, Raj S, Diedrich A, Shibao C, Robertson D . Nitric oxide and regulation of heart rate in patients with postural tachycardia syndrome and healthy subjects. Hypertension. 2013; 61(2):376-81. PMC: 3621717. DOI: 10.1161/HYPERTENSIONAHA.111.00203. View